Cargando…
Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer
Oesophageal cancer is a devastating disease with poor outcomes and is the sixth leading cause of cancer death worldwide. In the setting of resectable disease, there is clear evidence that neoadjuvant chemotherapy and chemoradiotherapy result in improved survival. Disappointingly, only 15%–30% of pat...
Autores principales: | Lavery, Anita, Turkington, Richard C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793050/ https://www.ncbi.nlm.nih.gov/pubmed/33442473 http://dx.doi.org/10.1093/gastro/goaa065 |
Ejemplares similares
-
A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
por: Foley, Kieran G., et al.
Publicado: (2021) -
Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
por: Jiang, William, et al.
Publicado: (2022) -
The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
por: Lang, Cameron C. J., et al.
Publicado: (2022) -
Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
por: El Mashed, Shereen, et al.
Publicado: (2022) -
Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
por: de Klerk, Leonie K., et al.
Publicado: (2021)